Mediar Therapeutics is planning to launch a Phase 2 clinical trial in the first half of 2025 to test its IPF therapy MTX-463.

Broadway performers will sing show tunes at a fundraising event aimed at boosting awareness of pulmonary fibrosis.

The internet is full of false claims. Columnist Sam Kirton shares why fact-checking is important, particularly for the rare disease world.

Visit the Pulmonary Fibrosis News forums to connect with others in the PF community.

Columnist Sam Kirton says that at his age, and as someone with pulmonary fibrosis, he's had much experience dealing with grief.

With idiopathic pulmonary fibrosis, columnist Sam Kirton continues to learn to be prepared for emergencies, such as the Los Angeles fires.

Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic ...

Blocking fatty acid synthase (FASN), an enzyme responsible for fatty acid production in cells, reduced the signs of induced idiopathic pulmonary fibrosis (IPF) in mice, according to a study ...